Incidence of plasma cell dyscrasia as a second primary malignancy may be low in postmenopausal breast cancer survivors treated with selective estrogen receptor modulator or aromatase inhibitor

✍ Scribed by Kadri Altundag; Mevlut Kurt; Rabiul Islam; Ozden Altundag; Selahattin Turen

• Book ID: 116742725
• Publisher: Elsevier Science
• Year: 2006
• Tongue: English
• Weight: 37 KB
• Volume: 66
• Category: Article
• ISSN: 0306-9877
• DOI: 10.1016/j.mehy.2005.05.005